{"filings":[{"id":860879,"accession_number":"0001628908-26-000037","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2026-06-04T20:05:16+00:00","items":["5.07"],"status":"ready","headline":"Evolent Health shareholders elect 10 directors, approve incentive plan amendment at June 4 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected with majority support; vote tallies range from 60.0M to 65.9M 'for' votes.","Advisory say-on-pay resolution approved 58.4M for vs 7.9M against (88% of votes cast).","Amendment to 2015 Omnibus Incentive Compensation Plan passed with 47.5M for, 18.7M against (71.8% of votes cast).","Ratification of Deloitte & Touche as auditor for FY2026 passed with 82.0M for, 0.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94202,"accession_number":"0001628908-26-000031","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Health Reports Q1 2026 Results; Revenue Up, Net Loss Narrowed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $496.2M vs $483.6M in Q1 2025; net loss improved to $26.6M from $72.3M.","Adjusted EBITDA $22.1M with margin 4.4%, down from $36.9M margin 7.6% prior year.","Signed new revenue agreements: advanced imaging solution for ~4.5M lives; oncology/cardiology expansion expected >$200M annual revenue.","CEO Seth Blackley highlighted successful oncology launches at Highmark and Aetna, focus on AI opportunity.","Medical expense ratio rose to 93.3% from 68% (84% excluding Evolent Care Partners)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":496246000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106401,"accession_number":"0001628908-26-000014","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Q4 2025 revenue $468.7M, net loss $429.1M; guides 2026 revenue up ~30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $468.7M, full-year $1.876B. Net loss $429.1M Q4, $579.4M full year.","Adjusted EBITDA $37.8M (8.1% margin) Q4; $151.2M (8.1% margin) full year.","Performance Suite average members 6,482 for year; $900M new Performance Suite revenue for 2026.","2026 revenue growth guidance ~30%; first-half Adj. EBITDA pressured by reservering and membership declines.","Medical expense ratio 90.2% Q4; 80.5% full year (excl. ECP 94.8% and 89.0%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":1876229000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122751,"accession_number":"0001628908-25-000145","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Evolent Health closes acquisition of Privia Management Company","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Acquisition closed on December 5, 2025, per Stock Purchase Agreement dated September 23, 2025.","Evolent Health LLC, a wholly owned subsidiary of Evolent Health, Inc., acquired Privia Management Company, LLC.","No financial terms, transaction value, or operational details disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122750,"accession_number":"0001628908-25-000141","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Evolent Health board adds Jill Smith as director; reaffirms Q4 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cheryl Scott retired from Board on Dec 1, 2025; no disagreement; 21,979 RSUs accelerated.","Jill Smith appointed to Board on Dec 2, 2025; term expiring at 2026 annual meeting; determined independent.","Ms. Smith brings 25+ years of leadership; ex-CEO of DigitalGlobe, Allied Minds; current director at Securitas, Check Point, MDA Space.","Reaffirmed Q4 2025 revenue guidance $462M-$472M and Adj. EBITDA $30M-$40M (unchanged from Nov 6)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122749,"accession_number":"0001628908-25-000132","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Evolent Q3 Adj EBITDA $39M (8.1% margin); new CFO Ramos; 2026 revenue forecast $2.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $479.5M, net loss $26.9M; adjusted EBITDA $39.0M vs $31.8M YoY.","Two new customer agreements bring YTD total to 13; >$750M new annualized revenue to launch in 2026.","Mario Ramos appointed CFO effective Jan 1, 2026; John Johnson becomes Chief Strategy Officer.","New CFO Ramos receives $550K base salary, $625K bonus, $100K sign-on bonus, and $2.35M RSU grant.","Katie DiPerna named COO; Emily Rafferty transitions to EVP Customer Success."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":1407510000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139435,"accession_number":"0001628908-25-000124","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Evolent sells value-based primary care business Evolent Care Partners to Privia for up to $113M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ECP acquired by Privia Health Group (PRVA) for $100M cash at close plus up to $13M contingent on 2025 MSSP performance; expected close Q4 2025.","All net proceeds will prepay senior term debt; transaction is accretive to free cash flow by >$7M/year net of reduced ECP cash generation.","ECP serves 120,000 members with 1,000+ physicians in Medicare Shared Savings Program; ~$10M current adjusted EBITDA.","Guides Q3 2025 rev $460-480M and Adj EBITDA $34-42M; FY2025 rev $1.85-1.88B and Adj EBITDA $140-165M excluding ECP.","CEO says divestiture allows focus on core specialty business and accelerates deleveraging; interest expense reduction ~$10M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139434,"accession_number":"0001193125-25-185388","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Evolent Health issues $166.75M of 4.50% convertible notes, repurchases existing notes and stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $166.75M aggregate principal of 4.50% convertible senior notes due 2031 at 100% par.","Used net proceeds of $161.2M plus liquidity to repurchase $167.4M of 1.50% convertible notes due 2025 for $167.6M.","Concurrently repurchased $40M of Class A common stock in privately negotiated transactions.","Initial conversion price of ~$13.53 per share, representing a 50% premium over August 18 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139433,"accession_number":"0001193125-25-183075","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Evolent prices upsized $145M convertible notes at 4.50%; uses proceeds to repurchase 2025 notes and common stock.","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced $145M (upsized from $140M) of 4.50% convertible senior notes due 2031; initial purchasers have 30-day option for additional $21.75M.","Conversion price ~$13.53/share, representing ~50% premium over $9.02 closing price on Aug 18, 2025.","Net proceeds estimated at $140.2M ($161.2M if option fully exercised), after fees and expenses.","Approximately $100.2M plus available liquidity to repurchase ~$167.4M of existing 1.50% 2025 notes; ~$40M to repurchase 4.43M common shares at $9.02/sh.","CFO states transaction avoids over $9M annual interest vs. credit facilities and extends next debt maturity to 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139432,"accession_number":"0001193125-25-182692","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Evolent Health Announces $140M Convertible Note Offering and Discloses DOJ Investigation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Evolent Health intends to offer $140.0M aggregate principal amount of convertible senior notes due 2031, with an option for an additional $20.0M.","The company plans to use up to $100M of net proceeds to repurchase a portion of its 1.50% convertible senior notes due 2025 and about $40M to repurchase shares of its Class A common stock.","Evolent disclosed it received a Civil Investigative Demand from the DOJ on August 12, 2025, regarding a False Claims Act investigation involving former customer's diagnosis codes since 2016.","The notes will be convertible into cash, stock, or a combination, subject to conversion rights termination conditions after August 20, 2026.","The offering is private under Rule 144A, and the securities are not registered under the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139431,"accession_number":"0001628908-25-000112","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Q2 revenue falls 31% to $444M, net loss deepens to $51M; raises FY profitability outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $444.3M, down 31% YoY from $647.1M; net loss $51.1M vs $6.4M loss in prior year.","Adjusted EBITDA $37.5M (8.5% margin) vs $51.9M (8.0% margin); margin improved but absolute EBITDA down 28%.","Performance Suite average lives 6,490, down 6% YoY; average PMPM fee $13.76, down 38% YoY.","CEO says company exceeded EBITDA targets and raised full-year profitability outlook; expects to exceed historical growth rates in 2026.","Year-to-date new revenue agreements total 11; multiple new client additions across Performance Suite and specialty services."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":927977000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157019,"accession_number":"0001628908-25-000098","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Evolent reaffirms FY2025 Adj. EBITDA guidance $135-165M; secures Ares non-dilutive financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirmed FY2025 Adj. EBITDA guidance $135-165M and Q2 2025 guidance $33-40M.","Oncology cost trend below expectations through May; if continues, expects Q2 Adj. EBITDA in top half of range.","Secured Commitment Letter with Ares for Incremental Facility to retire 2025 Convertible Notes; non-dilutive debt option.","Amendment No. 5 to Credit Agreement modifies liquidity test, adds default if Exchange not consummated.","Accelerating organic new revenue bookings forecast for 2026 go-lives due to high market demand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157018,"accession_number":"0001628908-25-000072","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Evolent Health reports 2025 annual meeting results; all directors elected, say-on-pay passes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten director nominees elected on June 5, 2025, including Toyin Ajayi, Seth Blackley, Kim Keck, Brendan Springstubb.","Ratification of Deloitte & Touche as auditor: 100,396,561 for, 21,620 against, 59,483 abstentions.","Say-on-pay approved with 77,588,031 for (88.4% of votes cast) vs 10,172,695 against.","Amendment to 2015 Omnibus Incentive Compensation Plan approved: 84,769,019 for, 3,033,271 against.","Board committees updated per cooperation agreement; Brendan Springstubb added to Audit and Compensation committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157017,"accession_number":"0001628908-25-000069","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Evolent Health reaffirms FY2025 revenue guidance of $2.06B-$2.11B at William Blair conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms FY2025 revenue guidance of $2.06B-$2.11B and Adjusted EBITDA of $135M-$165M.","Q2 2025 revenue guidance reaffirmed at $440M-$470M; Adj EBITDA $33M-$40M.","Guidance unchanged from the May 8, 2025 press release; no new financial targets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157016,"accession_number":"0001628908-25-000064","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Health Q1 revenue down 24% to $483.6M; net loss widens to $72.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $483.6M vs $639.7M YoY; net loss $72.3M vs $25.2M YoY.","Adjusted EBITDA $36.9M (7.6% margin) vs $54.1M (8.5% margin) YoY.","Five new revenue agreements added, including surgical management, oncology, and imaging expansions.","Performance Suite lives declined to 6,486 from 7,050 YoY; specialty technology lives rose to 77,079.","Company reiterates full-year 2025 revenue and Adjusted EBITDA outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":483649000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157015,"accession_number":"0001628908-25-000055","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Director Holder not re-standing; former CVS Health CFO Shawn Guertin nominated to Evolent board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Diane Holder will not stand for re-election at June 5, 2025 annual meeting; departure not due to any disagreement.","Board nominates Shawn Guertin, former EVP & CFO of CVS Health (2021-2023) and former CFO of Aetna, for election.","Guertin brings nearly 40 years of actuarial, financial and management experience in healthcare and insurance.","If elected, Guertin would be sixth new independent director added in past four years, continuing board refreshment.","Company expects to file proxy statement for the 2025 annual meeting; Guertin's nomination recommended by Nominating and Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175379,"accession_number":"0001628908-25-000018","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Q4 2024 revenue $646.5M (+16.3% YoY); net loss $30.6M, adjusted EBITDA $22.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2,554.7M full year 2024, +30.1% YoY; net loss $93.5M, net loss margin (3.7)%.","Adjusted EBITDA $160.5M full year 2024, margin 6.3%; Q4 adjusted EBITDA $22.6M, margin 3.5%.","Signed contract amendments in all three Performance Suite negotiations, expected $115M annual improvement for 2025 vs Q4 2024.","100% retention across top customers representing over 90% of 2024 revenue; new revenue agreements announced in Q4.","Average Performance Suite lives on platform 7,145 in Q4, average PMPM fee $21.32."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":2554741000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175378,"accession_number":"0001628908-25-000010","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"Evolent Health enters cooperation with Engaged Capital, appoints Springstubb to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Brendan Springstubb (Engaged Capital affiliate) to Board; he joins Strategy Committee.","Engaged Capital bound by standstill: cannot exceed 9.9% ownership or launch proxy contests.","M. Bridget Duffy resigned from Board effective Feb 3, 2025, not due to any disagreement.","Richard Jelinek to be named Chair of the Board at 2025 Annual Meeting, succeeding Cheryl Scott.","Board continues independent director search; five new independent directors added in three years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175377,"accession_number":"0001628908-25-000008","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["2.03"],"status":"ready","headline":"Evolent Health borrows $200M in delayed draw term loans for general corporate purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Jan 24, 2025, Borrower gave notice to draw $125M (2024-A) and $75M (2024-B) delayed draw term loans, funding Jan 31.","Proceeds for general corporate purposes including working capital and potential management of Convertible Notes due Oct 2025.","Interest rate at SOFR+5.50% or base+4.50%, with step-downs based on secured leverage ratio.","Term loans mature Dec 6, 2029, or earlier upon certain conditions including 180 days before 2029 Convertible Note maturity.","Prepayment premiums: 2% in year 1, 1% in year 2, 0% thereafter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175376,"accession_number":"0001628908-25-000004","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Evolent Health to present at JPM Healthcare Conference; no material new data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation scheduled for Jan 14, 2025 at 4:30 PM PT at the 43rd Annual J.P. Morgan Healthcare Conference.","Live webcast accessible via investor relations section of Evolent's website.","Exhibit 99.1 furnished as investor presentation; content not fully provided in this filing.","No specific financial guidance, earnings updates, or material business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192319,"accession_number":"0001628908-24-000117","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Evolent Health amends credit agreement adding $250M in new debt facilities","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Increased existing ABL revolver by $50M (with $25M funded); new delayed draw term loans of $125M and $75M.","Interest rates: ABL at SOFR + 4.00% or base + 3.00%; term loans at SOFR + 5.50% or base + 4.50%.","Maturity is earliest of 5 years from Dec 6, 2024, or 180 days before 2029 convertible notes maturity.","Borrowing under term loans requires total secured leverage ratio ≤ 2.00:1.00.","Upfront fees: 1% on ABL commitment; 2% (reducible to 1%) on term loan amounts funded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192318,"accession_number":"0001628908-24-000112","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Q3 revenue rises 21.6% to $621M, net loss $31.2M; EBITDA miss due to $42M medical cost spike","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $621.4M, up 21.6% YoY; net loss $(31.2)M vs $(33.2)M prior year.","Adjusted EBITDA $31.8M (5.1% margin), down from $48.7M (9.5%) YoY.","Medical costs exceeded expectations by $42M: $24M prior-period claims, $18M oncology spike.","Company revises 2024 Adjusted EBITDA guidance; reiterates long-term growth targets.","Record six new contracts signed, including oncology Performance Suite with top-5 payer (200k members)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":1908199000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208797,"accession_number":"0001628908-24-000089","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Q2 revenue $647M (+38% YoY); net loss narrows to $6.4M; Adj. EBITDA $52M; narrows FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $647.1M, up 37.9% YoY from $469.1M; net loss $(6.4)M vs $(41.4)M loss in Q2 2023.","Adjusted EBITDA $52.0M (8.0% margin) vs $47.4M (10.1% margin) in prior year.","Narrows full-year 2024 revenue outlook and updates Adjusted EBITDA guidance; reaffirms $300M exit run rate target.","Performance Suite average lives grew to 6,901 from 3,810 YoY; signed new oncology and specialty deals."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1286798000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226562,"accession_number":"0001628908-24-000080","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Evolent Health annual meeting: all 10 directors elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Diane Holder received 8.6M against votes (8.4% of votes cast).","Ratification of Deloitte as auditor: 109.9M for, 16k against, 86k abstain.","Advisory approval of 2023 executive compensation: 97.7M for (94.3% of votes cast), 5.95M against.","Board selects one-year frequency for future advisory votes on compensation (100.4M votes for 1 year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226561,"accession_number":"0001628908-24-000057","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Evolent Health acquires Machinify assets for $25M cash plus up to $7M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $25M plus up to $7M earn-out; perpetual royalty-free license of Machinify Auth AI platform.","Acquisition expected to close Q3 2024; includes re-badging certain Machinify employees and multi-year services agreement.","Machinify Auth currently reviews over $200B in medical claims annually; reduces clinician time by avg 55% for complex reviews.","Acquisition is immaterial to Evolent's revenue outlook and neutral to Adjusted EBITDA in first year after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226560,"accession_number":"0001628908-24-000051","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Health Q1 revenue $639.7M (+49.6% YoY); raises FY2024 revenue guide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $639.7M, net loss $(25.2)M; Adjusted EBITDA $54.1M (8.5% margin).","Raises full-year 2024 revenue outlook; reiterates Adjusted EBITDA and exit-rate guidance.","Ends NIA transition services agreement; partners with Careology to accelerate patient navigation.","New Performance Suite with Molina for oncology/cardiology in SC and MS; MSK contract with east coast Medicaid plan.","Performance Suite average lives 7,050 (up from 3,242 YoY); specialty care revenue grew over 60%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":639653000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245558,"accession_number":"0001628908-24-000015","cik":1628908,"company_name":"Evolent Health, Inc.","ticker":"EVH","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evolent Health Q4 revenue $556M, FY revenue $1.96B (+45%); net loss ($142M), adj EBITDA $194.7M (+84%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 revenue of $1,963.9M, up 45% YoY; net loss of $(142.3)M (net loss margin -7.2%).","Adjusted EBITDA of $194.7M, up 84% YoY; cash flow from operations of $142.6M.","Q4 2023 revenue $556.1M, net loss $(41.4)M, adjusted EBITDA $48.1M (8.6% margin).","Initial 2024 outlook: revenue growth ~25% at midpoint, consistent with long-term targets.","Announced four new revenue agreements, including first comprehensive oncology bundle and first Performance Suite for advanced imaging."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":556055000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":427428074.7849462,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}